Introduction
Arbekacin is an aminoglycoside that induces cell membrane damage and binds to both the 50S and 30S ribosomal subunits, resulting in codon misreading and inhibition of translation. 1 It shows a strong antimicrobial activity against Gram-positive bacteria, including MRSA. The antimicrobial activity of arbekacin against MRSA was equivalent to that of vancomycin. [1] [2] [3] [4] Additionally, arbekacin shows a good antimicrobial activity against Gram-negative bacteria, including Pseudomonas aerunigosa. 2, 5 Since Staphylococcus aureus and P. aeruginosa are the most frequent causative pathogens of hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), 5, 6 arbekacin might be useful for the treatment of patients with these diseases.
The therapeutic effectiveness of arbekacin is directly related to the fraction of the mean maximum drug concentration (C max ) at the infection site. The ratio of the C max of arbekacin in the epithelial lining fluid (ELF) to that in the serum is 0.40. 7 These data suggested that a higher dose is needed to treat patients with pneumonia than that needed for those with bloodstream infections. However, a higher dose will lead to a higher trough concentration (C trough ). It is reported that a high C trough of aminoglycosides increases the incidence of kidney-related adverse drug reactions, and therapeutic drug monitoring (TDM) is required to maximize the efficacy while V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. minimizing the toxicity of aminoglycosides. 1 In the 1990s, aminoglycoside formulations for inhalation, such as for tobramycin and amikacin, were developed to maximize drug delivery to the respiratory tract and minimize the toxicity. In this study, we investigated the in vivo efficacy of ME1100, a novel optimized formulation of arbekacin for inhalation, by using a customized investigational nebulizer system, and compared its efficacy with that of amikacin.
Materials and methods

Bacterial strains
The strain of P. aeruginosa used in this study was PANU3724, a clinical isolate obtained from the endotracheal tube of a patient at Nagasaki University Hospital. The bacteria were stored at #80 C in a Microbank V R bead preservation system (Pro-Lab Diagnostics, Ontario, CA) until use.
Antimicrobial agents
Amikacin sulphate injection was purchased from Sawai Pharmaceutical Co., Ltd (Osaka, Japan). ME1100 inhalation solution and placebo inhalation solution were supplied by Meiji Seika Pharma Co., Ltd (Tokyo, Japan). ME1100 is a novel formulation of arbekacin, which provides high concentration and stability for inhalation (International Application number PCT/ EP2012/065265). The aqueous liquid pharmaceutical composition of ME1100 inhalation solution comprises arbekacin and chloride ions. Through the use of this composition, the sulphate salt form of arbekacin, which causes a coughing reaction, was reduced.
Inhalation exposure system
The customized investigational eFlow V R rapid nebulizer system was supplied by Pari Pharma GmbH. The average of the mass median aerodynamic diameter of the ME1100 droplets generated by the nebulizer system was 3.7 + 0.1 lm, and $73% of the droplets were in the size range 0.5-5 lm.
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In this study, we constructed an original nose-only exposure system. We cut off the tip of the 50 mL conical centrifuge tubes, and held the mice in the tube in a posture such that their nose protruded from the tip of the tube. Subsequently, we put the tubes into a sealed container through which the flow generated by the nebulizer system passed.
Animals
We purchased specific pathogen-free male ICR mice (6-7 weeks old, 25-30 g bodyweight) from Japan SLC, Inc. (Shizuoka, Japan). The mice were housed in a pathogen-free environment and received sterile food and water in the Biomedical Research Center at Nagasaki University.
Ethics
All the experimental protocols used in this study were approved by the Ethics Review Committee for Animal Experimentation (approval number 1003310842).
Antimicrobial susceptibility tests
We determined the MIC of the antimicrobial agents against the PANU3724 strain by a microdilution method in accordance with the guidelines of the CLSI. 9 CLSI interpretative criteria (M100-S24) were applied for testing the susceptibility of the PANU3724 strain to the antimicrobial agents. 10 
Murine model of VAP
Disposable sterile plastic cut-down intravenous catheters with a gauge of 3 Fr (Atom Co., Tokyo, Japan) were used for tracheal intubation. The catheters were cut to a length of 5.0 mm and a few slits were made at the proximal end to prevent their clogging by oral secretions. The bacteria were cultured overnight on Mueller-Hinton II agar (Becton Dickinson, Le Pont de Claix, France). Then, they were suspended in sterile saline and the concentration was adjusted to 2 % 10 8 cfu/mL, as estimated by turbidimetry (DensiCHEK TM Plus: bioMérieux, Hazelwood, MO, USA). Inoculation was carried out as described previously. [11] [12] [13] [14] Briefly, the tube was inserted through the vocal cords into the trachea. Subsequently, P. aeruginosa suspended in saline solution (0.05 mL; 1 % 10 7 cfu/mouse) was inoculated through the outer sheath of the intravenous catheter.
Treatment protocol
ME1100 and amikacin were diluted with the placebo inhalation solution. Twelve hours post-inoculation, the mice were treated for 5 min, once daily, with placebo, 3, 10 or 30 mg/mL ME1100 or 30 mg/mL amikacin by using a customized investigational nebulizer system. In the survival study, the mice were treated for 108 h post-inoculation and the survival rates were observed for 120 h post-inoculation.
Bacteriological examinations
The mice were sacrificed at 18 h post-inoculation i.e. 6 h after the initial treatment, by cervical dislocation. Subsequently, they were dissected under aseptic conditions to collect the blood via a right ventricular puncture using heparin-coated syringes, and to remove the lungs. The lungs were suspended in 1 mL of normal saline and homogenized with a homogenizer (AS One Co., Osaka, Japan). Serial dilutions of the lungs and blood were quantitatively cultured in Mueller-Hinton II agar plates. After overnight incubation, we evaluated the number of the visible colonies. The lowest level of detectable bacterial count was 1 % 10 2 cfu/mL.
Collection of blood and bronchoalveolar lavage fluid (BALF) for pharmacokinetic studies
The mice were treated for 5 min with 30 mg/mL ME1100 or 30 mg/mL amikacin by using a customized investigational nebulizer system, and were then sacrificed by cervical dislocation at 5 and 30 min and 1, 3, 6 and 12 h post-inhalation. Blood was collected via a right ventricular puncture using heparin-coated syringes. BALF was also collected. Four mice were used for each group. The collection of BALF was performed as described previously. 15, 12 Briefly, the mice were sacrificed and the chest was opened to expose the lungs and trachea. A disposable, sterile, plastic cut-down catheter was inserted into the trachea. Bronchoalveolar lavage (BAL) was performed three times sequentially using 1.0 mL of saline each time. Blood and BALF were centrifuged and the supernatants were stored at #80 C until use.
Pharmacokinetic studies
The levels of arbekacin and amikacin in the plasma and BALF were measured by LC (LC-10Advp, Shimadzu) coupled with a tandem mass spectrometer (Quattro Ultima Pt, Waters). Dibekacin was used as an internal standard. All analytes were determined via measurement of a derivative formed by their reaction with phenyl isocyanate in the presence of triethylamine.
When the value of an assessed parameter of a pharmacokinetic sample was expected to exceed the upper limit of quantification, the sample was diluted 2-fold (plasma) or 5-fold (BALF) with blank plasma or BALF. Each plasma or BALF sample (10 lL) was transferred to a tube, and the standard solution (10 lL) and saline (180 lL) were added and mixed with a vortex mixer. The mixture (50 lL) was transferred to another tube, and the internal standard solution (50 lL), acetonitrile containing 0.5% triethylamine (50 lL), and acetonitrile containing 0.5% phenyl isocyanate (50 lL) were added and mixed with the vortex mixer. Then, methanol (400 lL) was Kaku et al.
added. The mixture was centrifuged at 9100 g for 5 min at 4 C. The supernatant (30 lL) was injected into the column of the LC-tandem MS system. Arbekacin and amikacin were chromatographically separated on an analytical column (Inertsil ODS-3, 2.1 % 50 mm, 5 lm, GL Sciences Inc.) using a gradient of water/formic acid (1000:1, v/v) with acetonitrile as the mobile phase at 40 C. The flow rate was set at 0.4 mL/min. The tandem mass spectrometer was operated in the positive ion mode. Arbekacin was monitored as the precursor ion at 1149 m/z and the product ion at 367 m/z. Amikacin was monitored as the precursor ion at 1062 m/z and the product ion at 409 m/z. Dibekacin (internal standard) was monitored as the precursor ion at 1048 m/z and the product ion at 367 m/z. The assay was linear over 0.05-5 mg/L for arbekacin and amikacin in mouse plasma and BALF. The accuracy of the assay method ranged between 88.9% and 114.2%.
Measurement of urea concentration in the plasma and BALF was conducted using an urea assay kit (Biochain Institute, Inc.) based on the Jung method. 16 The samples were diluted 50-fold (plasma) or 10-fold (BALF) with saline. The standard curve showed a linear range from 0.05 to 1 mg/dL. Arbekacin and amikacin concentrations in the ELF were calculated using the following equation because the ELF was diluted with saline: arbekacin (or amikacin) in ELF " arbekacin (or amikacin) in BALF % urea in plasma/urea in BALF. 17 For pharmacokinetc analysis, WinNonlin Professional Ver.6.3 (Pharsight Corporation) was used.
Statistical analysis
We used a statistical software package (StatMate V; ATMS Co., Ltd, Tokyo, Japan) for all the statistical comparisons. Survival rates were calculated using the Kaplan-Meier method. Survival analysis was performed using the log-rank test and the data were expressed as mean + SD. Bacterial counts in the lungs and blood were depicted as box-and-whisker plots and we analysed the differences between groups using one-way analysis of variance (ANOVA) followed by Tukey's post hoc test. All tests of significance were two-tailed. The a level for statistical significance was set at P , 0.05.
Results
MICs of antimicrobial agents for PANU3724
The MICs of arbekacin and amikacin for the bacterial strain PANU3724 were 4 and 8 mg/L, respectively. This bacterial strain exhibits resistance to carbapenems (Table 1) .
Therapeutic effects of antimicrobial agents on survival rate
In the survival study, the mice were treated according to the prescribed methods for 108 h post-inoculation and the survival rates were observed for 120 h post-inoculation (n " 7 in each group). As shown in Figure 1 , the survival rates were significantly higher in the 10 and 30 mg/mL ME1100 treatment groups than in the placebo treatment group (P , 0.001 for both groups). Additionally, the survival rate in the 30 mg/mL ME1100 treatment group was significantly higher than that in the placebo treatment group (P " 0.022).
Bacteriological examinations
Since some mice in the placebo treatment group died at 24 h postinoculation in the survival study, the mice were sacrificed 18 h post-inoculation i.e. 6 h after the initial treatment (n " 5 in each group).
The bacterial counts in the lungs of the mice receiving placebo, 3, 10 and 30 mg/mL ME1100 were 9.34 + 0.23, 9.20 + 0.33, 8.86 + 0.31 and 8.09 + 0.35 log 10 cfu/mL, respectively (Figure 2a) . The bacterial count in the lungs was significantly lower in the 30 mg/mL ME1100 treatment group compared with that in all other groups (P , 0.001 versus the placebo and the 3 mg/mL ME1100 treatment groups; P , 0.05 versus the 10 mg/mL ME1100 treatment group).
The bacterial counts in the blood of the mice receiving placebo, 3, 10 and 30 mg/mL ME1100 were 6.08 + 0.43, 5.36 + 0.96, 4.91 + 0.64, and 4.39 + 1.47 log 10 cfu/mL, respectively (Figure 2b) . The bacterial count in the blood was significantly lower in the 30 mg/mL ME1100 treatment group compared with that in all other groups (P , 0.001 versus the placebo and 3 mg/mL ME1100 treatment groups; P , 0.05 versus the 10 mg/mL ME1100 treatment group).
Comparison of ME1100 and amikacin
In the survival study, the mice were treated according to the prescribed methods for 108 h post-inoculation and survival rates were observed for 120 h post-inoculation (n " 6 in each group). As shown in Figure 3(a) , the survival rates were significantly higher in the 30 mg/mL ME1100 treatment group than in the placebo and 30 mg/mL amikacin treatment groups (P " 0.005 versus placebo and P " 0.024 versus amikacin).
In the bacteriological examination, the mice were sacrificed 18 h post-inoculation, i.e. 6 h after the initial treatment (n " 5 in each group). Bacterial counts in the lungs of mice in the placebo, 30 mg/mL ME1100 and 30 mg/mL amikacin treatment groups were 10.23 + 0.24, 9.51 + 0.27 and 10.20 + 0.05 log 10 cfu/mL, respectively (Figure 3b ). Bacterial count in the lungs was significantly lower in the 30 mg/mL ME1100 treatment group compared with counts in the placebo and amikacin treatment groups (P , 0.001 versus both groups). Efficacy and pharmacokinetics of ME1100 in VAP
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Pharmacokinetics of ME1100
The mice were treated for 5 min with 30 mg/mL ME1100, and then ELF and blood were collected at 5 and 30 min and 1, 3, 6 and 12 h post-inhalation. The calculated pharmacokinetic parameters of ME1100 are shown in Figure 4 (a) and Table 2 . The C max of ME1100 in the ELF and plasma was 31.1 and 1.2 mg/L, respectively. The AUC 0-1 values of ME1100 in the ELF and plasma were 67.7 and 2.2 mgÁh/L, respectively. The t 1/2 values of ME1100 in the ELF and plasma were 2.4 and 4.6 h, respectively. The ELF concentration of ME1100 was significantly higher than its plasma concentration at 5 and 30 min and 1 and 3 h post-inhalation (P " 0.028).
Comparison of the ELF and blood concentrations of ME1100 and amikacin
The mice were treated for 5 min with 30 mg/mL ME1100 or amikacin, and then ELF and blood were collected at 5 min and 1 h postinhalation. The concentrations of ME1100 in the ELF at 5 min and 1 h post-inhalation were 31.1 + 13.6 and 20.2 + 17.6, respectively, and those of amikacin were 46.7 + 16.1 and 19.1 + 13.3, respectively ( Figure 4b ). The concentrations of ME1100 in the plasma at 5 min and 1 h post-inhalation were 1.2 + 0.5 and 0.4 + 0.1, respectively, and those of amikacin were 2.5 + 1.7 and 0.5 + 0.2, respectively ( Figure 4c ). There was no significant difference between the ELF and blood concentrations of ME1100 and amikacin.
Discussion
Antimicrobial agents, such as tobramycin, colistin and aztreonam, have been administered via inhalation to patients with chronic respiratory tract infections caused by P. aeruginosa. P. aeruginosa has been a common cause of HAP, including VAP. 5, 6 Although there are several antipseudomonal agents, P. aeruginosa is associated with high in-hospital mortality and prolonged length of stay in hospital. 18 The treatment of P. aeruginosa infection has been difficult because the bacteria possess numerous mechanisms of antimicrobial resistance. Therefore, there is a need to develop novel antimicrobial agents effective against P. aeruginosa. In the ATS/IDSA guidelines, 19 combination therapy with aminoglycosides and b-lactams was recommended as an empirical treatment for patients with VAP caused by drug-resistant Gram-negative bacteria, including P. aeruginosa. However, this combination therapy for sepsis was discouraged due to the significant risk of nephrotoxicity. 20 To decrease the risk of nephrotoxicity, some aminoglycoside formulations were optimized in order to be administered via inhalation in patients with VAP. 21 In this study, ME1100, optimized for inhalation, showed good in vivo antimicrobial activity in a murine model of VAP caused by P. aeruginosa. In the survival study, ME1100 treatment (30 mg/mL) significantly improved the survival rate in comparison with the placebo group, in which the infected mice died within 48 h post-inoculation. In addition, ME1100 (30 mg/mL) significantly reduced the bacterial count in the lungs and blood when administered only once.
The primary purpose of the inhalation route is to maximize drug delivery to the target site of infection and limit the potential for systemic side effects. Arbekacin, a conventional formulation of ME1100, is classified as a kanamycin aminoglycoside. The therapeutic effectiveness of aminoglycosides is directly related to the C max , and a previous study reported that the probability of cure/improvement increased when the C max of arbekacin was increased. 22 In patients with pneumonia, the local concentration of antimicrobial agents at the infection Figure 1 . Therapeutic effects of ME1100 on survival rate. Twelve hours post-inoculation, the mice were treated for 5 min, once daily, with placebo or 3, 10 or 30 mg/mL ME1100. Survival was determined at the indicated time and the results are displayed as a Kaplan-Meier plot. The black triangles represent the times of treatment. Survival rates were observed for 120 h after inoculation (n " 7 in each group). *Survival rate in the 30 mg/mL ME1100 treatment group was significantly higher than rates in the placebo and 3 mg/mL ME1100 treatment groups (P , 0.001 versus placebo, and P " 0.022 versus 3 mg/mL ME1100). †Survival rate in the 10 mg/mL ME1100 treatment group was significantly higher than that in the placebo group (P , 0.001). site, such as ELF, is important. 23 A previous study on the intravenous administration of arbekacin reported that the ratio of the C max of arbekacin in the ELF to that in the serum is 0.40. 7 These data suggested that a higher dose of arbekacin would be needed to treat patients with pneumonia via intravenous administration rather than inhalation. In this study, the ratio of the C max of ME1100 in the ELF to that in the plasma was $25.9. Accordingly, ME1100 could contribute to the treatment of patients with VAP by maximizing drug delivery to the respiratory tract. However, there is a possibility of resistance emerging in patients with bacteraemia because the low C max of inhaled aminoglycosides in the plasma would facilitate drug resistance. Therefore, as described in the ATS/IDSA guidelines, 19 the combination of ME1100 and b-lactams might be recommended in clinical use.
Among the aminoglycosides optimized for inhalation, amikacin is frequently reported. Several clinical studies reported that administration of amikacin via inhalation is effective in patients with VAP. [24] [25] [26] In this study, we compared the in vivo efficacy and pharmacokinetics of ME1100 with those of amikacin. Although there were no significant differences in drug concentrations in ELF and plasma between ME1100 and amikacin, ME1100 significantly improved the survival rate compared with amikacin. However, the nebulizer system used in this study was customized for inhalation of ME1100. Additionally, we did not adjust the doses of ME1100 and amikacin based on their pharmacokinetics. The MIC of amikacin for the PANU3724 strain is higher than that of ME1100, and the calculated C max /MIC of amikacin was lower than that of ME1100 (5.8 for amikacin and 7.8 for ME1100). Since an optimized formulation of amikacin for inhalation, known as BAY41-6551 or NKTR-061, is under development, 24 it is necessary to compare ME1100 and the optimized amikacin formulation for inhalation in the future.
Some previous studies reported that arbekacin shows strong antimicrobial activity against Gram-positive bacteria, including MRSA. 3, 4 Since arbekacin is stable to the aminoglycosideinactivating enzymes produced by MRSA, it shows the most potent antimicrobial activity against MRSA among the aminoglycosides. 1 Additionally, the MIC required to inhibit the growth of 90% of organisms (MIC 90 ) of arbekacin against MRSA is 0.5 mg/L, which is lower than those of vancomycin and linezolid (1 and 2 mg/L, respectively). 1 Since P. aeruginosa and S. aureus, including MRSA, are the most and the second most frequently isolated pathogens from patients with VAP, 5 ME1100 might be useful for the treatment of patients with VAP.
There were some limitations in this study. First, we used only one clinical strain of P. aeruginosa and one mouse species. Second, it is very difficult to predict the efficacy of ME1100 in humans because ME1100 is still under development and the Black triangles represent the times of treatment. Survival rates were observed for 120 h after inoculation (n " 6 in each group). *Survival rate in the ME1100 treatment group was significantly higher than rates in the placebo and 30 mg/mL amikacin treatment groups (P " 0.005 versus placebo and P " 0.024 versus amikacin). (b) Six hours after initial treatment, the mice were sacrificed and the number of bacteria in the lungs was analysed (n " 5 in each group). Box-and-whisker plots show the range and median of the number of bacteria. The number of bacteria in the lungs was significantly lower in the ME1100 treatment group compared with the placebo and amikacin treatment groups ( †P , 0.001 versus both groups). . ELF and plasma concentrations of ME1100 and amikacin. The mice were treated for 5 min with placebo, 30 mg/mL ME1100 or amikacin (n " 4 in each group). (a) Concentrations of ME1100 in ELF and plasma were measured at 5 and 30 min and 1, 3, 6 and 12 h post-inhalation. *The concentration of ME1100 in the ELF was significantly higher than that in the plasma for 3 h post-inhalation (P " 0.028). Concentrations of ME1100 and amikacin in ELF (b) and plasma (c) were compared at 5 min and 1 h post-inhalation. There were no significant differences between ME1100 and amikacin concentrations in either ELF or plasma. Efficacy and pharmacokinetics of ME1100 in VAP JAC pharmacokinetics of ME1100 in humans remains unknown. Third, the amikacin sulphate injection used in this study was not optimized for inhalation. Finally, we did not investigate the toxicity of ME1100 and amikacin in this study.
In conclusion, the results of our study demonstrated the in vivo effectiveness of ME1100 and its superiority to amikacin. Further investigations, including clinical trials, are needed to determine the efficacy of ME1100 in patients with VAP.
